Clinically Validated Probiotics
Beyond Reporting - Safety surveillance analytics for medical devices...
From Snapshots to Movies
Maximising Patient Engagement in Clinical Trials
Electronic Logs - The next phase of execution maturity in pharma
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems
Scientist, University of Kansas
Dr Sagar Salave is a Scientist at the University of Kansas USA specializing in mRNALNP therapeutics and viral vaccine formulation With a background in major pharmaceutical MNCs including Lupin and Ciron Drugs he possesses extensive expertise in drug discovery and nanotechnologydriven RD He serves as an Associate Editor for Applied Biochemistry and Biotechnology Journal Springer and sits on the Ed...
Articles
Quercetin - A Super Food For Therapeutic Interventions
Quercetin a member of the flavonoid family found in regularly consumed foods has received interest in nutrition circles for its ability to alter various biological processes Quercetin is a yellow crystalline substance with a bitter taste that is entirely insoluble in cold water soluble in lipids and alcohol and very slightly soluble in hot water
Research Insights
New Developments For Antibody-drug Conjugate-based Therapeutic Approaches
Abstract The clinical success of Adcetris brentuximab vedotin and Kadcyla adotrastuzumab emtansine has sparked clinical development of novel ADCs These powerful anticancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues Despite the use of tumorspecific antibodies
Case Studies
Tablet Coating at Low Bed Temperatures with a Novel Coating Polymer
This study shows how to obtain elegant uniform coatings with zero visible defects and a practical coating solution for heat sensitive products For More Infromation Click Here
Techno Trends
HUTCHMED Introduces First-of-its-Kind Savolitinib for Gastric Cancer Treatment
HUTCHMED has introduced firstofitskind savolitinib for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction GEJ adenocarcinoma patients with mesenchymal epithelial transition factor MET amplification who have failed to responded to at least two standard treatments
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Generative AI and the New Era of Personalized Medicine
Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.
Role of Nutraceutical in Various Diseases - A Review
Shaikh Habeeba working as an assistant professor at matoshri institute of pharmacy dhanore yeola nashik Maharashtra India. She has completed post-graduation in pharmacognosy. Her area of research interest in herbal formulation development. She has published more than 20 research& review paper in various national international journal. One case study accepted as book chapter in international publication & attended 17 conference & presented 5 paper in international national conference also guided more than 5 students for the research project.
The Exosome Manufacturing Gap
Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.
Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.
Use of Steroids in COVID-19 patients
Anoop Kumar currently working as Assistant Professor in Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India. He has authored more than 70 research and review articles and 10 book chapters in International Journal of repute. His research interests are Drug repurposing, Meta-analysis, Risk and benefit analysis of drugs and Pharmacoeconomic studies.
Artificial Intelligence in Oncology
Nancy Kapila is a seasoned pharmaceutical consultant with over 5 years of varied experience and a Master’s in Pharmaceutics from Panjab University. She excels in drug mechanisms and interactions. Her career highlights include collaborating with numerous pharmaceutical companies and offering strategic insights and guidance. Nancy stands out for her dedication to keeping abreast of pharmaceutical advancements, regulatory changes, and emerging trends. She believes in continuous learning to navigate the industry’s complexities and provide innovative client solutions. Fascinated by the role of data analytics in decision-making, Nancy delves into data to uncover patterns and opportunities, offering evidence-based recommendations for process optimization, product development, and operational efficiency. Her career is driven by a relentless pursuit of knowledge, passion for data insights, and commitment to leading pharmaceutical companies towards success in a dynamic industry.
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
